Ellen Chiniara News Today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective upped by Stifel Nicolaus from $35.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.84% from the stock’s previous close. Other research analysts […]

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) traded down 1.9% during trading on Monday following insider selling activity. The stock traded as low as $36.22 and last traded at $36.49. 178,419 shares changed hands during trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at […]

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Kymera Therapeutics in a research report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.79) per share for the quarter. Leerink Partnrs currently has […]

Operator: Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.

WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

WATERTOWN, Mass., Jan. 04, 2023 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein... | January 4, 2023

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio  Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition will be immediately core earnings-a...

12 december 2020 kl 13:59 Greater scientific presence in immunology by adding Alexions innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZenecas broad-based revenue and the company will further globalise Alexions portfolio Enhanced...